New Trial

[Salmon4]

I’m about to start on a new trial drug . It is called OP 1250. Has anybody heard anything about this drug? The trial is called the Olema study. Thanks

[Hazelgreen]

If you google "OP 1250", you'll be referred to "Olema Oncology" which recently announced the new study you mentioned. The study seems to be just getting started so you are contributing to science by participating in it. I assume that your breast cancer is also in its early stages.

Best of luck, Cindy

[Salmon4 in reply to Hazelgreen]

Thanks!

[love2golfwell]

Have not heard of that trial but thank you for participating in it. Hope you have great success. Sending you hugs and prayers.

[Salmon4 in reply to love2golfwell]

Thanks for the hugs and prayers! I hope it’s successful for myself and others…

[Dragonfly2]

hello! Good for you that you got yourself into this promising trial…OP 1250 will be a better fulvestrant (we hope). I frisée more trials with other drugs that now use fulvestrant as an endocrine therapy. So many women and men out there who need a substantial improvement in the drugs available. Best of luck…🫶🏻🫶🏻

[Salmon4 in reply to Dragonfly2]

Thanks! I hope this becomes a new treatment option for all of us with the ESR1 mutation!

[mariootsi]

You are a hero for doing a trial. I have such admiration for women brave enough to try these for the benefit of all

[Salmon4 in reply to mariootsi]

Thanks for your kind words! I hope it’s successful and it will be another option for others!

[TammyCross]

Look at this! Sounds really good. Not a risk to participate. I want in. I guess my hospital is not participating.

"Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 3 clinical trial, OPERA-01, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Palazestrant has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor."

This is a blurb from a presentation Olema is doing at a health care conference.

[Salmon4 in reply to TammyCross]

Thanks for the detailed information I will be taking the OP 1250 with Kisqali. I start in 2 weeks! Hope it’s successful and also helps others in the future….